Im­mat­ics imag­ines broad­er CAR-T pipeline with an­oth­er Bris­tol My­ers pact and ad­di­tion to 2019 TCR deal

Im­mat­ics is hit­ting the gas ped­al on an­oth­er Bris­tol My­ers Squibb deal as the biotech-Big Phar­ma pair al­so lev­el up their 2019 pact, orig­i­nal­ly inked with Cel­gene.

While the Ger­man-Hous­ton biotech is still in its ear­ly-stage clin­i­cal de­vel­op­ment days, Bris­tol My­ers likes what it has seen and wants to dive deep­er in­to Im­mat­ics’ T-cell ther­a­py plat­forms. That in­cludes $60 mil­lion up­front for a new deal and an­oth­er $20 mil­lion now for an ex­pan­sion to the 2019 col­lab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER